Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Fumarate SCHEMBL6133836 | 0.87 | HCAR2 (0.48) | TSHRHCAR2TDP1MAPTATM | |
| SCHEMBL1423548 | 0.82 | TSHR (0.50) | TSHRHPGDTDP1ATMCYP3A4 | |
| Ethyl Fumarate SCHEMBL11211795 | 0.80 | TSHR (0.76) | TSHRHCAR2HPGDTDP1ATM | |
| Ethyl Fumarate SCHEMBL11211796 | 0.80 | TSHR (0.76) | TSHRHCAR2HPGDTDP1ATM | |
| SCHEMBL16412765 | 0.79 | TSHR (0.47) | TSHRTDP1ATMCYP3A4RECQL | |
| SCHEMBL27506490 | 0.78 | TSHR (0.61) | TSHRHCAR2HPGDTDP1ATM | |
| Ethyl Fumarate SCHEMBL27854702 | 0.78 | HCAR2 (0.65) | TSHRHCAR2HPGDMAPTCACNA1B | |
| Ethyl Fumarate SCHEMBL460704 | 0.78 | HCAR2 (0.65) | TSHRHCAR2HPGDMAPTCACNA1B | |
| SCHEMBL1547531 | 0.77 | TSHR (0.67) | TSHRHCAR2HPGDTDP1ATM | |
| Acrylic Acid Ethyl Ester SCHEMBL8181478 | 0.77 | TSHR (0.64) | TSHRHCAR2HPGDTDP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050226919-A1 | Device for transdermal administration for the treatment of urinary tract disorders | UCB PHARMA GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| EP-1293198-B1 | Device for transdermal administration for the treatment of urinary tract disorders | SANOL ARZNEI SCHWARZ GMBH (DE) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003024432-A2 | DEVICE FOR TRANSDERMAL ADMINISTRATION FOR THE TREATMENT OF URINARY TRACT DISORDERS | SCHWARZ PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
| EP-1293198-A1 | Device for transdermal administration for the treatment of urinary tract disorders | SCHWARZ PHARMA AG (DE) | 2003-03-19 | — | — | EP | disclosed |
| US-5393529-A | Sustained release | LTS LOHMANN THERAPIE-SYSTEME GMBH & CO. KG (DE) | 1995-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050226919-A1 | Device for transdermal administration for the treatment of urinary tract disorders | AR, CYP17A1, TACR1 | TSHR 465/4885HCAR2 504/4885HPGD 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.